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SuMMAry Acute myeloid leukemia (AML) is a clonal expansion of my-
eloid blasts in peripheral blood, bone marrow, or other tissues. Cutane-
ous manifestations of leukemia are either specific or nonspecific. Spe-
cific lesions result from direct infiltration of the skin by leukemic cells. We 
present a case of myeloid leukemia cutis manifested by erythematous 
asymptomatic nodules and plaques distributed on the chest, abdomen 
and back. The clinical and histopathologic features of the cutaneous in-
filtrate were suggestive of hematolymphoid malignancy, more towards 
lymphoma. However, the immunohistochemical features were against 
the diagnosis of lymphoma and were highly suspicious of myeloid leu-
kemia, which were concomitantly confirmed by bone marrow biopsy 
and blood smear. In any poorly differentiated malignant skin infiltrate 
of confirmed hematopoietic lineage, myeloid differentiation should be 
considered and excluded by an appropriate panel. CD56+ AML is a rare 
type of AML that has special features like the great liability of extramed-
ullary involvement including skin, monocytic characteristic of leukemia 
cells, and absence of myeloperoxidase expression. 
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INtroDuCtIoN
Acute myeloid leukemia (AML) is a clonal expan-
sion of myeloid blasts in peripheral blood, bone mar-
row, and other tissues (1). It is a heterogeneous dis-
ease clinically, morphologically and genetically, and it 
may involve one or all myeloid lineages (myeloblast, 
monoblast/promonocyte, megakaryoblast). The di-
agnosis requires the presence of more than 20% of 
blasts in peripheral blood or bone marrow. Myeloid 
leukemia cutis is a described entity that refers to cu-
taneous involvement by leukemic cells, consisting of 
myeloblasts and myeloid cells in varying stages of dif-
ferentiation (2).   
Skin lesions are rare in AML and may be nonspecif-
ic or specific due to direct skin infiltration by leukemic 
cells. The rate of skin involvement in AML has been 
reported to be 5%-15% in adults and 30% in children 
(3). The most commonly described specific lesions are 
erythematous or violaceous plaques, papules or nod-
ules. Less common appearances include maculae, 
maculopapules or plaques (3). Other lesions may be 
present like gingival hypertrophy or leonine face (4). 
There are no predilection sites for skin involvement, 
but lower extremities followed by upper extremities, 
trunk and face are the most commonly reported sites 
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(3,5). In adults with AML, leukemia cutis represents a 
higher tumor burden and tends to be predictive of a 
prolonged and less favorable course (6).    
In this report, we describe a rare and special entity 
of myeloid leukemia cutis that simulates cutaneous 
lymphoma clinically and histopathologically, shows 
co-expression of CD56 and CD68, and lacks myelo-
peroxidase expression.
CASe rePort
We report a case of a 64-year-old male present-
ing with erythematous asymptomatic nodules and 
plaques of two-week duration. Lesions were distrib-
uted on the chest, abdomen (Fig. 1a) and back of the 
trunk (Fig. 1b). Generally, the patient had marked pal-
lor, fever and hepatosplenomegaly. Clinically, the pic-
ture was highly suggestive of lymphoma. 
Biopsy was obtained from one of the represen-
tative skin nodules, which was then submitted to 
routine tissue processing in Pathology Department, 
Faculty of Medicine. Hematoxylin and eosin stained 
sections revealed dermal infiltration by neoplastic 
monomorphous cells invading collagen bundles and 
separated from the overlying epidermis by a grenz 
zone (Fig. 2a). The neoplastic infiltrate was formed 
of intermediate to large cells showing scanty and 
deeply basophilic cytoplasm, large vesicular nuclei, 
prominent nucleoli and frequent mitoses (Fig. 2b). 
Immunophenotypically, the tumor cells showed dif-
fuse and strong positivity for LCA (Fig. 2c), CD56 (Fig. 
3a) and CD68 (Fig. 3b), but they were negative for 
myeloperoxidase (Fig. 2d), CD34 (Fig. 3c), CD3, CD20, 
CD30, CD123, LMP1, chromogranin, HMB-45 and 
pancytokeratin. 
These histopathologic and immunohistochemi-
cal features of the neoplastic infiltrate in cutaneous 
nodules necessitated further clinical investigations to 
clarify their nature. Therefore, complete blood picture 
was performed and showed increased total leukocyte 
count (18.2x106/mm3) with myeloid blast cells in pe-
ripheral blood smear. Bone marrow biopsy was also 
done and showed 90% infiltration by myeloblasts, 
which confirmed the diagnosis of AML. Abdomino-
pelvic ultrasonography showed hepatosplenomega-
ly and enlarged para-aortic lymph nodes. 
DISCuSSIoN 
When leukemia cutis occurs in the course of the 
disease, it is usually concomitant with the diagnosis 
of systemic leukemia, as in our case, or it may precede 
the diagnosis of systemic leukemia, which is then 
called aleukemic leukemia (5).   
The main differential diagnosis in the case we 
studied is cutaneous lymphoma. However, the histo-
pathologic picture of the cutaneous infiltrate was not 
compatible with the clinical features of mycosis fun-
goides, since the infiltrate was confined to the dermis 
with the absence of epidermotropism together with 
the absence of nuclear characteristics of T cell lym-
phoma that featured marked irregular nuclear mem-
brane and complete negativity for CD3. The possibil-
ity of non-Hodgkin’s lymphoma of B cell origin was 
suspected, especially with the presence of neoplastic 
infiltrate in the dermis, but the neoplasm was com-
pletely negative for CD20. Additional examinations 
using CD30, chromogranin, CK and HMB-45 were per-
formed to reveal the absence of their expression, thus 
excluding anaplastic lymphoma, Merkel cell carcino-
ma, other epithelial tumors and melanoma, respec-
tively. The positivity for LCA (CD45) was an impor-
tant finding because it raises suspicion of leukemic 
infiltration. LCA positivity has been reported in 90% 
of myeloid leukemia cutis (7). Therefore, the patient 
underwent bone marrow biopsy and complete blood 
count, which confirmed the diagnosis of AML.   
On the other hand, the neoplastic cells were dif-
fusely positive for CD56 and CD68. CD56 is an isoform 
of neural adhesion molecule (N-CAM). It is considered 
a natural killer cell marker, but it is also expressed by 
Figure 1. Erythematous nodules and plaques affect-
ing (A) the abdomen and (B) back of the trunk.
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normal T lymphocytes and some myeloid cells (8). 
There is a group of rare lymphoproliferative cutaneous 
lesions characterized by CD56 positivity, which include 
hematodermic neoplasm/blastic NK-cell lymphomas/
blastic plasmacytoid dendritic cell neoplasm, CD56+ 
acute myeloid leukemia, nasal-type extranodal natural 
killer/T-cell lymphoma and  ‘classic’ cases of cutane-
ous T-cell lymphoma (CTCL) with co-expression of the 
CD56 molecule (9).    
Absence of angio-invasion, necrosis and angio-de-
struction together with the lack of LMP1 expression 
exclude nasal-type extranodal natural killer/T-cell lym-
phoma. Absence of T cell marker expression excludes 
‘classic’ cases of cutaneous T-cell lymphoma (CTCL) with 
co-expression of the CD56 molecule. Diffuse positivity 
for CD68 with absence of CD123 expression excludes 
hematodermic neoplasms/blastic NK-cell lymphomas 
(9). Therefore, the picture was highly suggestive of my-
eloid leukemia cutis, which was concomitantly accom-
panied by systemic leukemia. 
Skin involvement may reach up to 20%-30% in 
AML, which is more common in myelomonocytic and 
monoblastic/monocytic differentiation (10). In the case 
described, several lines of evidence referred to this dif-
ferentiation, starting with monomorphous morphol-
ogy, absence of cytoplasmic granularity and diffuse 
expression of CD68. Some authors recommend the 
use of CD68 in the diagnostic panel for myeloid leuke-
mia cutis in challenging cases (11). The lack of myelo-
peroxidase and CD34 expression goes with this mono-
cytic differentiation. CD56+ myeloid leukemia displays 
more frequently an extramedullary involvement (skin, 
lymph node) at initial presentation (12), together with 
monocytic differentiation of leukemic cells (13).   
Myeloperoxidase is a microbicidal protein, which 
is present in the primary granules of myeloid cells and 
takes part in the defense of the body. It is synthesized 
in promyelocytes, where it is packed into azurophilic 
granules (14). Detection of myeloperoxidase indicates 
myeloid differentiation, but its absence does not ex-
clude a myeloid lineage because early myeloblasts as 
well as monoblasts may lack myeloperoxidase (15). 
Our case showed negative myeloperoxidase expres-
sion, which was considered as one of the challenging 
results to reach an accurate diagnosis. This negativity 
may be explained by the loss of cellular differentiation 
or maturation. It has been reported that decreased 
myeloperoxidase activity in polymorphonuclear leu-
kocytes in AML may contribute to the increased sus-
ceptibility to infections (16).   
Figure 2. The dermis is infiltrated by a population of monomorphous cells that leave grenz zone from the overly-
ing epidermis (A); neoplastic cells are large, with scanty and deeply basophilic cytoplasm, large vesicular nuclei, 
prominent nucleoli and frequent mitoses (H&E staining, X100 for A, X400 for B) (B); positive and diffuse immu-
nohistochemical staining for LCA in the neoplastic cells (C); negative immunoreactivity for myeloperoxidase 
(immunohistochemical staining, X400 for C and D) (D).
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CoNCLuSIoN
Involvement of skin in case of AML may be the 
first presentation that sometimes simulates cutane-
ous lymphoma clinically. The histopathologic features, 
immunophenotyping, and bone marrow biopsy are 
greatly helpful in reaching an accurate diagnosis. In any 
poorly differentiated malignant skin infiltrate of con-
firmed hematopoietic lineage, myeloid differentiation 
should be considered and excluded by an appropriate 
panel. CD56+ AML is a rare type of AML that has spe-
cial features like the great liability for extramedullary 
involvement including skin, monocytic characteristic 
of leukemia cells, and absence of myeloperoxidase 
expression. 
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Figure 3. The neoplastic infiltrate shows diffuse and strong positivity for CD56 (A) and CD68 (B), but lacks expres-
sion of CD34 (immunohistochemical staining, X400).
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